UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/523,738	10/13/2005	Shinjiro Domi	KIT-382	7696
	7590 03/30/200 & JAWORSKI, LLP	EXAMINER		
666 FIFTH AV	Е		VETERE, ROBERT A	
NEW YORK, NY 10103-3198			ART UNIT	PAPER NUMBER
			1792	
			MAIL DATE	DELIVERY MODE
			03/30/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/523,738	DOMI ET AL.
Office Action Summary	Examiner	Art Unit
	ROBERT VETERE	1792
The MAILING DATE of this communication a Period for Reply	ppears on the cover sheet with the	correspondence address
A SHORTENED STATUTORY PERIOD FOR REP WHICHEVER IS LONGER, FROM THE MAILING  - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period.  - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the mai earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATIO 1.136(a). In no event, however, may a reply be ti od will apply and will expire SIX (6) MONTHS from ute, cause the application to become ABANDONE	N. mely filed n the mailing date of this communication. ED (35 U.S.C. § 133).
Status		
1) ☐ Responsive to communication(s) filed on <u>04</u> 2a) ☐ This action is <b>FINAL</b> . 2b) ☐ The solution of the condition of the c	nis action is non-final. vance except for formal matters, pr	
Disposition of Claims		
4)  Claim(s) 1-16 is/are pending in the application 4a) Of the above claim(s) is/are withdrest is/are allowed.  5)  Claim(s) is/are allowed.  6)  Claim(s) 1-16 is/are rejected.  7)  Claim(s) is/are objected to.  8)  Claim(s) are subject to restriction and constant is a subject to restriction and constant is objected to by the Examination.  4 The drawing(s) filed on 04 February 2005 is/a	rawn from consideration.  /or election requirement. ner.	ed to by the Examiner
Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the left	ne drawing(s) be held in abeyance. Se ection is required if the drawing(s) is ob	ee 37 CFR 1.85(a). ojected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
<ul> <li>12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority docume</li> <li>2. Certified copies of the priority docume</li> <li>3. Copies of the certified copies of the priority docume</li> <li>* See the attached detailed Office action for a list</li> </ul>	ents have been received. Ents have been received in Applicat Fiority documents have been receive Feau (PCT Rule 17.2(a)).	ion No ed in this National Stage
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 9/05.	4)  Interview Summary Paper No(s)/Mail D 5)  Notice of Informal I 6)  Other:	oate

Application/Control Number: 10/523,738 Page 2

Art Unit: 1792

## **DETAILED ACTION**

## Claim Rejections - 35 USC § 103

- 1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 2. Claim 1 is rejected under 35 U.S.C. 103(a) as being unpatentable over Tanaka et al. (Ceramic Society of Japan, 10/2000, p. 280, translation provided by applicant) in light of Deki et al. (JP 09-278488, Machine Translation).
- Claim 1: Tanaka teaches a method of forming ferromagnetic particles comprising the steps of: contacting particles with a solution of fluorine and iron (p. 1:23-25), forming a layer of FeOOH on the particles (2:10-12), and heating the particles to produce a ferromagnetic layer (1:26-29, 2:10-12). What Tanaka fails to teach is that a reaction initiator is added to the process. Deki, however, teaches a method of coating a substrate with hematite (¶ 0030) comprising the steps of providing a solution containing fluorine and iron, forming a layer of FeOOH (¶ 0028) and heating the coating to form hematite (¶¶ 0029-0030), wherein boric acid is added as a reaction initiator (¶ 0011). The selection of a known material based on its suitability for its intended use supported a prima facie obviousness determination in *Sinclair & Carroll Co. v. Interchemical Corp.*, 325 U.S. 327, 65 USPQ 297 (1945). Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have added boric acid in the method of Tanaka with the predictable expectation of success because both Tanaka and Deki teach substantially similar methods of forming ferromagnetic layers.
- 3. Claims 2-3 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tanaka and Deki in light of Ohtsu et al. (US 5,179,170).
- Claims 2-3: Tanaka and Deki fail to teach that the reaction initiator is added successively.

  However, Ohtsu teaches that it is well known in the art of reaction initiators to add reaction initiators gradually to a mixture so that the initiator does not decompose in the solution (5:38-45). Thus, it would

Art Unit: 1792

have been obvious to one of ordinary skill in the art at the time the invention was made to have added the boric acid gradually to the solution in the combined method of Tanaka and Deki in order to prevent the boric acid from decomposing in the solution.

4. Claims 4-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tanaka, Deki and Ohtsu in light of Maruhotora et al. (JP 08-106902, machine translation).

Claims 4-5: With respect to the pH content of the solution, Deki teaches that the amount of acid in the solution can be adjusted (¶ 0028). "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." *In re Aller*, 105 USPQ 233, 235 (CCPA 1955). Thus, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have selected a pH range which provided the desired results.

With respect to the limitation regarding the concentration of fluorine to iron and of iron on its own, Tanaka teaches that the solution contains a saturation concentration of iron (1:23-25) and Deki does not expressly teach the ratio of iron to fluorine, but rather teaches the amount of the various ingredients (¶ 0028). Maruhotora teaches a method of forming an iron oxide layer comprising the steps of producing a FeOOH layer from a solution containing fluorine and iron in the presence of boric acid and heating the FeOOH obtained to form hematite (¶ 0012). Maruhotora also teaches that the molar ratio of FeOOH to NH<sub>4</sub>F-HF is 1:5 (¶ 0012), but does not expressly teach the ratio of Iron to Fluorine. A range can be disclosed in multiple prior art references instead of in a single prior art reference depending on the specific facts of the case. *Iron Grip Barbell Co., Inc. v. USA Sports, Inc.*, 392 F.3d 1317, 1322, 73 USPQ2d 1225, 1228 (Fed. Cir. 2004). Further, "where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." *In re Aller*, 105 USPQ 233, 235 (CCPA 1955). Thus, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have selected an appropriate ratio of iron to fluorine in the combined method of Tanaka and Deki with the predictable expectation of success because the art teaches that a variety of ratios yield desirable results.

Claims 6-7 and 16: Tanaka also teaches that the iron raw martial is  $Fe_3O_4$  (1:23-25). Maruhotora also teaches that iron fluoride is used as the iron raw material (¶ 0010). The selection of a

Application/Control Number: 10/523,738 Page 4

Art Unit: 1792

known material based on its suitability for its intended use supported a prima facie obviousness determination in *Sinclair & Carroll Co. v. Interchemical Corp.*, 325 U.S. 327, 65 USPQ 297 (1945). Thus, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have used iron fluoride as the raw material in the combined method of Tanaka and Deki with the predictable expectation of success.

Claims 8-9: Tanaka further teaches that the iron material is dissolved in HF (1:23-25).

Maruhotora further teaches that the iron material is dissolved in a mixed solution of an ammonium fluoride and HF (¶ 0012). The selection of a known material based on its suitability for its intended use supported a prima facie obviousness determination in *Sinclair & Carroll Co. v. Interchemical Corp.*, 325 U.S. 327, 65 USPQ 297 (1945). Thus, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have used a solution of HF and an ammonium fluoride in the combined method of Tanaka and Deki with the predictable expectation of success.

Claims 10-13: As discussed above, both Deki and Maruhotora teach that the reaction initiator is boric acid.

Claims 14-15: Tanaka teaches that the solution is heated under the same conditions as those listed in applicant's specification ( $70CO_2 + 30H_2$ , 1:26-29), but doesn't teach that gamma hematite is produced. However, because the reaction conductions are identical, it is inherent that at least some gamma hematite is produced.

5. Claims 14-15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tanaka, Deki, Ohtsu and Maruhotora in light of Matsui et al. (US 5,468,210) and Huisman et al. (US 4,349,385).

Claims 14-15: Tanaka teaches that the ferromagnetic particles are produced for use in hyperthermal cancer treatment (title), but does not expressly teach that the ferromagnetic coating is gamma hematite. However, Matsui teaches that gamma hematite is a useful substitute for magnetite in thermal treatment of tumors (1:17-37). Furthermore, Huisman teaches that FeOOH can be converted to gamma hematite by heating FeOOH under a hydrogen atmosphere (4:14-24). Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have produced gamma hematite rather than magnetite in the method of Tanaka with the predictable expectation of

Application/Control Number: 10/523,738 Page 5

Art Unit: 1792

success because it is known in the art of hyperthermal tumor treatment that gamma hematite produces

results similar to magnetite.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should

be directed to ROBERT VETERE whose telephone number is (571)270-1864. The examiner can

normally be reached on Mon-Fri 9-6.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor,

Michael Cleveland can be reached on 571-272-1418. The fax phone number for the organization where

this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application

Information Retrieval (PAIR) system. Status information for published applications may be obtained from

either Private PAIR or Public PAIR. Status information for unpublished applications is available through

Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC)

at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative

or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-

1000.

/Robert Vetere/

Examiner, Art Unit 1792

/Michael Cleveland/

Supervisory Patent Examiner, Art Unit 1792